Core Insights - The Ministry of Industry and Information Technology and the National Development and Reform Commission have initiated a program to cultivate over 20 pilot platforms for biomanufacturing by 2027, aiming to facilitate industrial scale-up [1] - Significant technological breakthroughs and industrial layouts are emerging in the biomanufacturing sector, with advancements in areas such as polysulfone plastic recycling and wool sterol synthesis [1] - The synergy between policy support and industrial development is accelerating the transition of biomanufacturing from laboratory research to large-scale industrialization, showcasing a vibrant development chain of "technological breakthroughs - policy support - capital influx" [1] Industry Developments - Synthetic biology is reshaping production models in biomanufacturing, enabling tasks that traditional biotechnologies cannot achieve, while also providing more efficient and environmentally friendly biosynthesis solutions [1] - Companies like Huaxi Biological and Yikole are extending their capabilities in synthetic biology, with Huaxi focusing on the supply chain of hyaluronic acid and Yikole leveraging CRISPR-Cas9 technology for precise gene editing [2][3] - The integration of synthetic biology with traditional industries is seen as a means to enhance productivity and create new growth opportunities, rather than a conflict [4] Technological Innovations - Companies are developing comprehensive systems in synthetic biology, focusing on tool, platform, and product integration, with significant advancements in production efficiency [3] - AI is playing a crucial role in enhancing research efficiency in synthetic biology, with companies establishing AI teams to optimize data collection and algorithm development [7] - The use of AI in the design and testing phases of synthetic biology is expected to significantly reduce research timelines and costs, improving overall productivity [7] Market Trends - The biomanufacturing industry is experiencing a wave of policy support, with various local governments implementing initiatives to promote the industrialization of synthetic biology [8] - The market for biomanufacturing in China is projected to approach 1.8 trillion yuan by 2030, indicating substantial growth potential [8] - Recent financing trends show an acceleration in investments in domestic synthetic biology companies, with nearly a hundred firms securing new funding at the beginning of 2025 [8] Future Outlook - The synthetic biology sector is anticipated to undergo rapid technological iterations and deeper application expansions in the next 3-5 years, driven by AI advancements [9] - Companies are encouraged to focus on quality improvement and original design rather than mere scale expansion, to avoid resource wastage and industry chaos [9] - The industry is expected to face dual challenges in technology transfer and industrialization, particularly in constructing microbial cell factories and overcoming engineering challenges in fermentation and purification [10]

#全球政策进展 | 上海市 关于上海市2025年度关键技术研发计划"合成生物学"项目拟立项项目的公示 根据市科技计划项目管理办法有关规定，现将上海市2025年度关键技术研发计划"合成生物学"项目拟 立项项目予以公示。 | 图源：上海市科学技术委员会 | | --- | 公示链接：http://svc.stcsm.sh.gov.cn/public/guide 公示期：2025年6月12日至2025年6月18日 对公示内容持有异议的，请于公示期内以书面形式向我委反映。按照市科研失信行为调查处理办法有关 规定，个人提出异议的，请在异议材料上注明姓名和联系电话；单位提出异议的，请在异议材料上加盖 单位公章，并注明联系人和联系电话。我委对异议者的信息予以保密。为保证异议处理客观、公正、公 平，保护被公示者的合法权益，我委对匿名且无明确证据和可查线索的异议，不予受理。 材料寄送至：市科委科技人才处（上海市人民大道200号，邮编200003）。 投诉举报电话：60286858 业务咨询电话：8008205114（座机）、4008205114（手机） 上海市科学技术委员会 2025年6月12日 上海市2025年度关键技术研发 ...

# SynBio团队 | 中科院苏州医工所马富强 在人工生命体精准编程的"黄金时代"，合成生物学作为融合工程学、计算机科学与分子生物学的交叉学科， 正通过"设计-构建-测试"的循环模式重塑生物制造范式。这一领域不仅被列为全球科技竞争的战略高地，更在 医药研发、碳中和、农业升级等关乎国计民生的赛道上展现出颠覆性潜力。 其核心突破点聚焦 三大支柱 ： 三大支柱技术如同精密咬合的齿轮，共同决定了细胞合成工厂的效率 。 【SynBioCon】 获 悉，近日， 苏州医工所马富强研究团队 围绕上述合成生物学三大支柱技术开展了系统工 作： 图2. 利用深度学习辅助生成新型启动子的两种方法 ： 左 图 ， 通过对现有启动子引入突变或随机生成新序列 来创建新的序列。这些新生成的序列通过启动子识别模型进行筛选，以验证其功能 ；右 图 ， 使用扩散模型 或生成对抗网络（GANs）来生成新的启动子。扩散模型通过添加高斯噪声逐步生成启动子序列。GANs 由生 成器和判别器组成，生成器负责生成假样本，而判别器用于区分真实样本和生成的假样本。通过训练过程不 断优化生成器的性能，使其能够生成更逼真的启动子序列。 工作1 ： 新型酶资源 的 ...

Core Insights - A team from Colorado State University has successfully synthesized a "gene switch" that allows for the flexible activation or deactivation of key genetic traits in mature plants, marking a significant advancement in synthetic biology [1][2] - This research provides a theoretical and technical foundation for the programmable regulation of plant gene functions, enabling tailored design of plant characteristics for various applications [2] Group 1: Research Significance - The study represents a milestone in synthetic biology, enabling the creation of a genetic "switch" that functions similarly to an electronic circuit, allowing precise control over gene expression in response to external signals [1] - Prior to this, gene regulation technologies were limited to single-celled organisms, making this achievement in complex multicellular plants particularly noteworthy [1] Group 2: Applications and Future Prospects - The "gene circuit" developed can regulate different stages of plant life cycles and has potential applications in agriculture and materials science, such as enhancing drought resistance in crops or optimizing growth cycles for better yield and nutritional value [2] - Future advancements may include the use of machine learning to further optimize the design process of gene circuits, potentially automating operations and accelerating research and development [2] - This breakthrough technology is expected to contribute to food security and open new possibilities in environmental restoration and sustainable materials development, representing a significant step towards the "programming" of plant modifications [2]

Core Viewpoint - The research conducted by Washington University and Altius Biomedical Science Institute successfully designed synthetic enhancers that are more efficient and simpler than natural enhancers, achieving unprecedented cell-type specificity in human cells through iterative deep learning technology [2][6]. Group 1: Research Challenges - Traditional enhancer discovery faces three major challenges: the vast number of candidate enhancers in the human genome, the lack of precision in existing enhancers that often activate multiple cell types, and the complexity of regulatory rules involving various transcription factor combinations and spatial arrangements [6]. Group 2: Research Methodology - The research team developed an iterative deep learning design system, which underwent two cycles of "design-experiment-optimize," starting from 29,891 natural enhancer MPRA activity data to train the model, resulting in the design of 1,037 synthetic enhancers [6]. - The model was refined using real measurement data of synthetic enhancers, reducing the training data volume by 30 times compared to previous generations, and introducing L2 regularization to prevent over-reliance on a single transcription factor [6]. - The second generation achieved a breakthrough with the design of 688 new enhancers, significantly increasing median expression levels in specific cell types, such as a 46.2-fold increase in HepG2 cells and a 6.7-fold increase in K562 cells [6][7]. Group 3: Research Highlights - The specificity of the deep learning-designed enhancers surpassed that of natural controls, and the sequence grammar used for synthetic enhancers was more compact than that of natural enhancers [8]. - Iterative retraining of synthetic enhancers led to designs with superior specificity, and the activity of synthetic enhancers was correlated with single-cell transcription factor expression [8]. Group 4: Applications - The research opens three major application directions: targeted gene therapy for liver cancer, customized tissue-specific enhancers for rare genetic diseases, and the construction of cell-type-specific biosensors in synthetic biology [10]. - This study marks a fundamental shift in the design paradigm of gene regulatory elements, moving from traditional methods to an AI-driven approach that significantly increases success rates [10].

Core Insights - The beauty industry is increasingly leveraging technology, with significant investment activity observed in May, indicating a recovery in the financing market after a brief lull [2][3]. Investment Overview - In May, there were at least 63 disclosed financing events globally, with a total financing amount of approximately 21.9 billion RMB [2]. - The beauty sector accounted for 12 financing events, totaling 9 billion RMB, while the AI sector had 35 events totaling 9.9 billion RMB [3]. Financing Characteristics - Among the 12 beauty financing events, 2 were in skincare (17%), 3 in color cosmetics/fragrance/personal care (25%), and 7 in raw materials/manufacturers/R&D (58%) [4]. - Notably, seed and angel rounds comprised 38% of the total financing events, indicating a strong interest in innovative investment opportunities [3]. Major Acquisitions - A significant acquisition in May was the purchase of the skincare brand Rhode, founded by Hailey Bieber, by Elf Beauty for 1 billion USD (approximately 72 billion RMB) [7][9]. - Another notable transaction involved Shinsegae Group and Ascent Equity Partners acquiring a controlling stake in C&C International for 285 billion KRW (approximately 14.9 billion RMB) [9][10]. Emerging Trends - The beauty financing landscape shows a trend where leading companies are actively pursuing large-scale financing, with multiple 1 billion USD deals emerging [6]. - Companies with strong founder backgrounds are more likely to attract investment, as seen with PMD and its founder's extensive experience in the skincare industry [11][12]. Focus on Synthetic Biology - Synthetic biology companies are leading the beauty sector's financing in May, with several firms receiving significant investments, including a strategic partnership between L'Oréal and the company Weiming Shiguang [14]. - The trend indicates a sustained interest in innovative materials and technologies within the beauty industry [14]. New Consumption and E-commerce - In the new consumption and e-commerce sectors, 16 brands received financing, with a notable focus on short video and cross-border e-commerce services [21][22]. - The pet industry also saw significant investment, with companies like Paitexian Sheng and Guochong Blood receiving angel round financing [24][25].

Group 1: Company Overview - Zhongchuang Xinhang, formerly known as AVIC Lithium Battery, has transformed from a struggling entity into a leading player in the power battery industry, ranking fourth globally in battery installation volume [2][3] - The company underwent a strategic overhaul under the leadership of Liu Jingyu, shifting focus from lithium iron phosphate batteries to ternary lithium batteries and from commercial vehicles to passenger vehicles [3][4] - In 2022, Zhongchuang Xinhang successfully listed on the Hong Kong Stock Exchange, becoming the first power battery stock in Hong Kong [3] Group 2: Strategic Initiatives - The company is expanding its operations by acquiring control of Suao Sensor, a leading automotive sensor company, which will provide a platform for its first listing in the A-share market [4] - Zhongchuang Xinhang is enhancing its technological capabilities by upgrading its information technology center to a digital intelligence center, focusing on smart manufacturing and customer satisfaction [4][5] - The company plans to transition to a matrix organizational structure in 2024, establishing four business units to improve resource allocation and achieve strategic goals [5] Group 3: Future Goals and Market Position - By 2025, Zhongchuang Xinhang aims to achieve breakthroughs in fast charging, range, and solid-state battery technologies, with a goal to rank among the top three globally in battery installation volume within the next 3 to 5 years [6] - The company has secured agreements with major international automakers such as Toyota, Volkswagen, Ford, and Audi for power battery orders, and has signed a significant energy storage project in Europe with a capacity of 4.4 GWh [6] - Zhongchuang Xinhang is actively pursuing global expansion, with ongoing projects including a €2 billion battery factory in Portugal and a module factory in Thailand [6]

Core Viewpoint - Synthetic biology and biomanufacturing are gaining significant attention and support from various sectors, including government, academia, and industry, highlighting their potential as new productive forces in the economy [1][17]. Event Overview - The SynBio China Third China Synthetic Biology "Scientists + Entrepreneurs + Investors" Expo will be held on August 1-2, 2025, at the Suzhou International Expo Center, featuring over 20,000 participants [3][33]. - The expo will include seven sub-conferences focusing on various aspects of synthetic biology, including health, food, and beauty industries [3]. Industry Challenges - Despite rapid dissemination of synthetic biology concepts in China, the industry faces challenges such as achieving scalable production, realizing product value, market exploration, and innovation in core competitiveness [17]. Applications and Innovations - Synthetic biology is driving innovations in functional ingredients, next-generation food additives, and personalized health foods, showcasing its transformative potential in the food industry [11][12]. - The technology is also advancing in the beauty sector, with applications in functional skincare ingredients and medical aesthetics [15][18]. Collaboration and Networking - The event aims to facilitate collaboration among innovators, industry experts, and investors, providing a platform for project promotion and industry guidance [20].

Core Viewpoint - Synthetic biology and biomanufacturing have gained significant attention and support from various sectors, including government, academia, and industry, highlighting their importance in driving innovation and economic growth in the biological economy [1][17]. Group 1: Event Overview - The SynBio China Third China Synthetic Biology "Scientists + Entrepreneurs + Investors" Expo will be held on August 1-2, 2025, at the Suzhou International Expo Center [3]. - The expo will feature seven sub-conferences, including discussions on synthetic biology applications in health, food, and cosmetics [3][11][15]. - The event aims to gather over 20,000 participants, showcasing the growing interest and investment in synthetic biology [3][33]. Group 2: Industry Challenges and Opportunities - Despite rapid concept dissemination, the synthetic biology industry in China faces challenges such as scaling production, realizing product value, and fostering market development [17]. - Synthetic biology is viewed as a key to understanding life and a disruptive technology that can significantly enhance China's biological economy [17]. - The industry is focused on promoting collaboration between research and enterprises to facilitate the translation of scientific achievements into practical applications [17][20]. Group 3: Technological Innovations - Advances in synthetic biology include the development of high-throughput reactors, enzyme catalysis, and microbial drug synthesis, which are crucial for biomanufacturing [8][12][15]. - Innovations in functional ingredients and personalized health foods driven by synthetic biology are expected to reshape the food industry [11][14]. - The application of synthetic biology in cosmetics and medical aesthetics is also being explored, with a focus on bio-synthesized ingredients [15][18].

Financial Performance - In Q1 2025, the company achieved a revenue of 1.296 billion CNY, a year-on-year decrease of 14.85% [4] - The net profit attributable to shareholders in Q1 2025 was 288 million CNY, down 18.26% year-on-year [4] - The decline in performance is attributed to a price adjustment for 6-APA and an increase in R&D expenses [4] Product Development and Production - The company has completed the pilot test for PHA production but has no plans for large-scale production due to the need for downstream application development [2] - Ongoing research projects in animal feed are being conducted, but there are no plans for direct sales of end products [2] - The planned production capacity for ergotamine is 0.5 tons, which can be adjusted based on market demand [11] Strategic Initiatives - The company aims to leverage AI and synthetic biology to enhance antibiotic production and improve operational efficiency [5] - Plans include reducing production costs through process improvements and lean management [5] - The company is focused on achieving a revenue target of 100 million CNY from synthetic biology by 2025 [12] Market Position and Collaborations - The company is positioned as a product-oriented entity in synthetic biology, with several products already in production and sales stages [10] - Collaborations with companies like Kelun Pharmaceutical focus on high-value natural products and biopharmaceuticals [6] - The company is actively exploring partnerships with international firms to expand its market reach [13] Regulatory Environment - The Chinese government has implemented various policies to promote the development of synthetic biology, including the "14th Five-Year Plan" for bio-economy [8] - The company is not significantly affected by tariff issues, as only 10% of its revenue comes from direct exports, primarily to India and Hong Kong [13]